학술논문
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
Document Type
Article
Author
Dimopoulos, Meletios Athanasios ; Hungria, Vania T M; Radinoff, Atanas; Delimpasi, Sosana; Mikala, Gabor; Masszi, Tamas; Li, Jian; Capra, Marcelo; Maiolino, Angelo; Pappa, Vasiliki; Chraniuk, Dominik; Osipov, Iurii; Leleu, Xavier; Low, Michael; Matsumoto, Morio; Sule, Neal; Li, Mary; McKeown, Astrid; He, Wei; Bright, Shelley; Currie, Brooke; Perera, Sue; Boyle, Julia; Roy-Ghanta, Sumita; Opalinska, Joanna; Weisel, Katja
Source
In The Lancet Haematology October 2023 10(10):e801-e812
Subject
Language
ISSN
2352-3026